Diallyl Trisulfide (H2S donor) 二烯丙基三硫

【溫馨提示】：見我司整理的硫化氫（H2S）熒光探針產(chǎn)品專題—WSP-1/WSP-5/AzMC。

產(chǎn)品簡(jiǎn)介：

二烯丙基三硫（Diallyl Trisulfide, DATS）是一種大蒜中發(fā)現(xiàn)的有機(jī)多硫化物，用作一種天然的硫化氫（H₂S）供體。DATS能夠減少前列腺癌細(xì)胞PC-3的存活率（IC50=22 μM）和抑制人結(jié)腸腺癌細(xì)胞HCT15的生長(zhǎng)（IC50=11.5μM）。體內(nèi)，DATS阻抑前列腺癌PC-3細(xì)胞裸鼠移植瘤生長(zhǎng)，誘導(dǎo)血管平滑肌松弛。

產(chǎn)品特性：

CAS NO.：2050-87-5

化學(xué)名：di-2-propen-1-yl trisulfide

同義名：DATS; NSC 651936;二烯丙基三硫醚；二烯丙基三硫化物；

分子式：C6H10S3

分子量：178.34

外觀：液體

純度：≥95%

溶解性：溶于DMSO（≥10mg/ml）、乙醇（≥5mg/ml）、不溶于水

化學(xué)結(jié)構(gòu)圖：

保存條件: 

-20oC保存，至少1年穩(wěn)定。

產(chǎn)品使用：【源自文獻(xiàn)，僅作參考】

文獻(xiàn)1：

體外研究（In Vitro Assay）：

細(xì)胞類型（Cell type）：BGC-823 and GSE-1 cell

實(shí)驗(yàn)方法（Cell viability assay）：The sulforhodamine B (SRB) assay was performed as described to measure BGC-823 and GSE-1 cell viability after DATS treatment. Briefly, 3.0×103 cells/well were grown in 96-well plates for 12 h and exposed todifferent concentrations of DATS (0–400 μmol/L) for 24 or 48 h.

體內(nèi)研究（In Vivo Assay）：

動(dòng)物模型（Animal Model）：Tumor xenograft mice model

實(shí)驗(yàn)方法（Assay）：To establish gastric carcinoma xenograft tumors in mice, BGC-823 cells (5.0×106) were suspended in 100 μL PBS and subcutaneously injected into the mice. The mice were sacrificed a month later. The tumor was separated by 2 mm fragments and implanted into other mice. When tumor volumes reached approximately 100 mm3,mice were randomized and assigned to the following treatments: control (normal saline, containing 20% β-cycloamylose, every day); cisplatin (5 mg/kg, positive control, every 5 d); treated groups (DATS was formed with β-cycloamylose and dissolved in normal saline, dosage at 20, 30 or 40 mg·kg?1·d?1); and the co-treated group (cisplatin, 5 mg/kg every 5 d and DATS at 30 mg/kg all other days). All mice were sacrificed on the 32nd day,and the tumors were excised for weight measurement and histopathological analysis.

文獻(xiàn)2：

體內(nèi)研究（In Vivo Assay）：

動(dòng)物模型（Animal Model）：Tumor xenograft mice model

配制方法（Formulation）：DATS was maintained in sealed amber glass ampules and kept at?20°C until use. On the day of experimentation, a fresh glass ampule of DATS was opened. DATS (5μl) was diluted in 500 μl of 100% DMSO. For in vivo experiments, the DATS in 100% DMSO solution was further diluted in sterile saline to obtain the correct dosage to be delivered in a volume of 50 μl. The resulting concentration of DMSO in this dosage was 1%. Vehicle consisted of a solution of 1% DMSO in sterile saline.

實(shí)驗(yàn)方法（Assay）：DATS was administered at 200 μg/kg before reperfusion by either an intravenous injection 5 min before reperfusion or an intraperitoneal injection 22.5 min before reperfusion.After 24 h of reperfusion, the LV area at risk (AAR) and infarct size were determined by Evan's blue and 2,3,5-tetrazolium chloride staining, as previously described.

注意事項(xiàng)：

1.      本品并非商業(yè)化的臨床藥物，僅用作科研用途，不得用作臨床診斷或治療，不得用于食品或藥品，絕對(duì)禁止用在人身上。

2.      為了您的安全和健康，請(qǐng)穿實(shí)驗(yàn)服并戴一次性手套操作。

相關(guān)產(chǎn)品：